Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.
brain tumor
deterioration-free-survival
progressive disease
time-to-deterioration
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
pubmed:
12
4
2022
medline:
3
12
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression-free time, and factors associated with HRQoL deterioration in this period. We included longitudinal HRQoL data from previously published clinical trials in glioma. The percentage of patients with stable HRQoL until progression was determined per scale and at the individual patient level (i.e. considering all scales simultaneously). We assessed time to a clinically relevant deterioration in HRQoL, expressed in deterioration-free survival and time-to-deterioration (the first including progression as an event). We also determined the association between sociodemographic and clinical factors and HRQoL deterioration in the progression-free period. Five thousand five hundred and thirty-nine patients with at least baseline HRQoL scores had a median time from randomization to progression of 7.6 months. Between 9-29% of the patients deteriorated before disease progression on the evaluated HRQoL scales. When considering all scales simultaneously, 47% of patients deteriorated on ≥1 scale. Median deterioration-free survival period ranged between 3.8-5.4 months, and median time-to-deterioration between 8.2-11.9 months. For most scales, only poor performance status was independently associated with clinically relevant HRQoL deterioration in the progression-free period. HRQoL was maintained in only 53% of patients in their progression-free period, and treatment was not independently associated with this deterioration in HRQoL. Routine monitoring of the patients' functioning and well-being during the entire disease course is therefore important, so that interventions can be initiated when problems are signaled.
Sections du résumé
BACKGROUND
Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression-free time, and factors associated with HRQoL deterioration in this period.
METHODS
We included longitudinal HRQoL data from previously published clinical trials in glioma. The percentage of patients with stable HRQoL until progression was determined per scale and at the individual patient level (i.e. considering all scales simultaneously). We assessed time to a clinically relevant deterioration in HRQoL, expressed in deterioration-free survival and time-to-deterioration (the first including progression as an event). We also determined the association between sociodemographic and clinical factors and HRQoL deterioration in the progression-free period.
RESULTS
Five thousand five hundred and thirty-nine patients with at least baseline HRQoL scores had a median time from randomization to progression of 7.6 months. Between 9-29% of the patients deteriorated before disease progression on the evaluated HRQoL scales. When considering all scales simultaneously, 47% of patients deteriorated on ≥1 scale. Median deterioration-free survival period ranged between 3.8-5.4 months, and median time-to-deterioration between 8.2-11.9 months. For most scales, only poor performance status was independently associated with clinically relevant HRQoL deterioration in the progression-free period.
CONCLUSIONS
HRQoL was maintained in only 53% of patients in their progression-free period, and treatment was not independently associated with this deterioration in HRQoL. Routine monitoring of the patients' functioning and well-being during the entire disease course is therefore important, so that interventions can be initiated when problems are signaled.
Identifiants
pubmed: 35404443
pii: 6566436
doi: 10.1093/neuonc/noac097
pmc: PMC9713503
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2159-2169Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Références
Lancet Oncol. 2008 May;9(5):453-61
pubmed: 18452856
Phys Ther. 2020 Mar 10;100(3):564-574
pubmed: 32043148
Lancet Oncol. 2014 Aug;15(9):943-53
pubmed: 25035291
Biometrics. 1984 Sep;40(3):601-9
pubmed: 6394063
BMJ Open. 2018 Jan 10;8(1):e019117
pubmed: 29326191
Neuro Oncol. 2021 Aug 2;23(8):1327-1336
pubmed: 33598685
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):90-100
pubmed: 30716525
Neuro Oncol. 2019 Nov 4;21(11):1447-1457
pubmed: 31682733
Adv Ther. 2011 Apr;28(4):334-40
pubmed: 21432029
J Clin Oncol. 2007 Dec 20;25(36):5723-30
pubmed: 18089866
Curr Neurol Neurosci Rep. 2013 Jul;13(7):359
pubmed: 23666388
AJR Am J Roentgenol. 2009 Dec;193(6):W515-22
pubmed: 19933626
Lancet Oncol. 2016 Nov;17(11):1533-1542
pubmed: 27686943
Qual Life Res. 1996 Feb;5(1):139-50
pubmed: 8901377
J Clin Oncol. 2015 Jul 1;33(19):2166-75
pubmed: 26014298
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Support Care Cancer. 2012 Oct;20(10):2315-25
pubmed: 22160582
J Clin Oncol. 1990 Jul;8(7):1277-80
pubmed: 2358840
Eur J Cancer. 2010 Oct;46(15):2753-62
pubmed: 20724140
Psychooncology. 2009 Nov;18(11):1129-38
pubmed: 19319920
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
JAMA Oncol. 2018 Sep 1;4(9):1254-1262
pubmed: 29931168
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
Eur J Cancer. 2012 Jul;48(11):1713-21
pubmed: 22418017
Eur J Cancer. 2015 Jul;51(10):1321-30
pubmed: 25899986
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
Neurosurgery. 2019 Aug 1;85(2):273-279
pubmed: 29917115
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
JAMA Oncol. 2018 Apr 01;4(4):495-504
pubmed: 29392280
Oncologist. 2011;16(10):1458-68
pubmed: 21948650
Neuro Oncol. 2009 Feb;11(1):51-8
pubmed: 18617599
Br J Cancer. 2000 Sep;83(5):588-93
pubmed: 10944597
Eur J Cancer. 2010 Apr;46(6):1033-40
pubmed: 20181476
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237